Noninvasive assay monitored treatment response in patients with metastatic prostate cancer

Deciding the ideal treatment for patients with metastatic prostate cancer that stops responding to initial therapy could be guided by certain analyses of cancer cells isolated from the patients' blood, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

"The growth and survival of are very dependent on signals that the cancer cells receive through a protein called the androgen receptor," said Daniel A. Haber, M.D., Ph.D., director of the Massachusetts General Hospital Cancer Center in Boston and project leader of the Stand Up To Cancer and Clinical Applications of Circulating Tumor Cell Chip Dream Team. "Treatments that deprive the androgen receptor of its signals are initially highly effective in most patients with metastatic prostate cancer. Unfortunately, prostate cancer, like all cancers, undergoes evolution during therapy, and this can confer resistance to treatment."

Haber and his colleagues established a way to isolate cancer cells from the blood of patients with prostate cancer and to measure readouts of androgen receptor signaling in each of the individual cancer cells in the blood.

Prior to the initiation of androgen-deprivation therapy, the androgen receptor signaling pathway was turned on in most of the cancer cells in the blood of patients with newly diagnosed metastatic prostate cancer. After the initiation of androgen-deprivation therapy, the pathway turned off in the circulating .

However, in patients whose prostate cancer had progressed after initially responding to androgen-deprivation therapy, the cancer cells in the blood were highly variable. Some cells had the androgen receptor signaling pathway turned on while other cells had it turned off. Yet other cells had characteristics of the signaling pathway being both on and off. The presence of cells with a mixed androgen receptor signaling pattern was associated with an adverse .

In addition, in patients treated with a new drug, abiraterone, which achieves more complete androgen deprivation than earlier treatments, an increased percentage of with androgen receptor signaling turned on despite abiraterone treatment was associated with decreased overall survival.

"This study is a proof of principle that it is possible to monitor, in patients with metastatic prostate cancer, the signaling pathway in real time, repeatedly and noninvasively," Haber said. "Our approach allowed us to monitor whether initial androgen-deprivation therapy was keeping the androgen signaling pathway shut down or whether the tumor was becoming resistant, and if so, by what mechanism."

"As more drugs are developed that target the different pathways that drive the recurrence of metastatic in different patients, it will become essential to know which drug and which pathway is relevant in each patient," he said. "Our assay will be an effective way to interrogate the tumor and follow it during the course of treatment to monitor therapy response and the emergence of drug resistance."

Related Stories

Study identifies new prostate cancer drug target

Feb 06, 2012

Research led by Wanguo Liu, PhD, Associate Professor of Genetics at LSU Health Sciences Center New Orleans, has identified a new protein critical to the development and growth of prostate cancer. The findings are published ...

Recommended for you

Blood biomarker may detect lung cancer

3 hours ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

ACG: Recent increase in incidence of young-onset CRC

19 hours ago

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments